Luxembourg

GSK Stockmann advised Art-Invest Real Estate on the sale of the Momenturm office building, located in Munich’s Werksviertel district, to Generali. The European commercial law firm has provided ongoing support to Art-Invest Real Estate with the project since the initial acquisition of the property. Art-Invest Real Estate has sold the Momenturm project to Generali Deutschland. The transaction was carried out by Generali Real Estate S.p.A. on behalf of Generali Deutschland. The existing approx. 11,000 sqm of office space in the building, located at Rosenheimer Strasse 139, just a stone’s throw away from Munich Ostbahnhof, is to be extended to around 28,000 sqm. Generali Deutschland plans to use the building as its new corporate headquarters, with 1,500 employees expected to be relocated there. A GSK Stockmann team led by Munich-based partner Dirk Brückner has been providing Art-Invest Real Estate with comprehensive support on this project since it first acquired the property back in 2019. The firm’s advice encompassed project structuring, project development and securing planning permission, as well as the sale to Generali. Art-Invest Real Estate is a long-standing client of GSK Stockmann. Most recently, the law firm advised the company on the acquisition of a hotel portfolio in 2024, which included properties in Berlin, Oberhausen, Koblenz and Frechen near Cologne. Other past projects include the acquisition of the Wangen office campus in Stuttgart and the Arnulfbogen in Munich, both in 2021, as well as the commercial property F150 on the Frankfurter Ring in Munich and the City-Passage in Wiesbaden, both in 2022. Advisers of Art-Invest Real Estate at GSK Stockmann: Dr Dirk Brückner (lead), Dr Mark Butt (both Real Estate Transactions & Investments), Stefan Dorn (Project Development), Stefan Wachsmuth (Tax), Katharina Feierabend (Real Estate Transactions & Investments); Associates: Sebastian Gerhards (Tax), Maximiliane Bartsch, Melanie Patrizia Seitz (both Real Estate Transactions & Investments), Leonie Lindenbuß (Project Development) GSK München Contact: GSK STOCKMANN Dr Dirk Brückner Karl-Scharnagl-Ring 8 80539 Munich T +49 89 288174 - 71 F +49 89 288174-44 [email protected] Press contact: GSK STOCKMANN Christina Holl Karl-Scharnagl-Ring 8 80539 Munich T +49 89 288174-275 F +49 89 288 174-44 [email protected]   GSK Stockmann is a leading independent European corporate law firm. Over 250 professionals advise German and international clients at our locations in Berlin, Frankfurt/M., Hamburg, Heidelberg, Munich, Luxembourg and London. GSK is the law firm of choice for Real Estate and Financial Services. We also have deep-rooted expertise in key sectors including Funds, Capital Markets, Public, Mobility, Energy and Healthcare. For international transactions and projects, we work together with selected reputable law firms abroad. Our advice combines an economic focus with entrepreneurial foresight. That is what is behind:  Your perspective. More about us: www.gsk.de  

European commercial law firm GSK Stockmann provided the Arsipa Group, backed by Warburg Pincus, with comprehensive legal advice on its acquisition of the Munich-based occupational healthcare provider Betriebsmedizin-23 GmbH. This represents a further step in Arsipa’s strategic expansion in the field of occupational medicine and also strengthens its presence in Bavaria. The acquisition provides a long-term succession solution for the well-established occupational medicine practice Betriebsmedizin-23, ensuring continuity of service for its clients in the greater Munich area. Under the management of Dr Markus Heyenbrock, the practice provides services primarily to small and medium-sized companies in the industrial, service, healthcare and public sectors. Its scope of services includes standard occupational health services, medical check-ups, vaccinations, advice on risk assessments and mental stress, as well as workplace integration management and occupational health and safety training. Following the acquisition, Betriebsmedizin-23 will benefit from the digital management solutions offered by the Arsipa Group, which will enable it to optimise its administrative processes and ultimately improve medical care. The acquisition takes the Arsipa Group’s network to over 60 locations serving more than 22,000 companies. A team led by Berlin-based partner Robert Korndörfer advised the Arispa Group on the acquisition. GSK Stockmann has a proven track record in providing expert advice on transactions in the healthcare sector, having previously advised Arsipa on its acquisition of the occupational healthcare provider Betriebsärzte Allgäu. Advisers of Arsipa at GSK Stockmann: Robert Korndörfer (lead, Corporate), Clara López Hernando (Corporate), Stephan Wachsmuth (Tax), Nicole Deparade (Employment Law), Katrin Zukovskaja (Employment Law), Dr Martin Hossenfelder (IP/IT), Dr Maximilian Schnebbe (Data Protection) Contact: GSK STOCKMANN Robert Korndörfer Anton-Wilhelm-Amo-Str. 42 10117 Berlin T +49 30 203907 - 93 F +49 30 203907-44 [email protected] Press contact: GSK STOCKMANN Christina Holl Karl-Scharnagl-Ring 8 80539 Munich T +49 89 288174-275 F +49 89 288 174-44 [email protected] GSK Stockmann is a leading independent European corporate law firm. Over 250 professionals advise German and international clients at our locations in Berlin, Frankfurt/M., Hamburg, Heidelberg, Munich, Luxembourg and London. GSK is the law firm of choice for Real Estate and Financial Services. We also have deep-rooted expertise in key sectors including Funds, Capital Markets, Public, Mobility, Energy and Healthcare. For international transactions and projects, we work together with selected reputable law firms abroad. Our advice combines an economic focus with entrepreneurial foresight. That is what is behind: Your perspective. More about us: www.gsk.de

GSK Stockmann advised the Arsipa Group on the acquisition of Betriebsärzte Allgäu, a well-established occupational healthcare provider based in Kempten. This acquisition will expand Arsipa’s presence in one of the strongest economic regions in southern Germany. A GSK Stockmann team led by Berlin partner Robert Korndörfer provided the Arsipa Group with comprehensive legal advice on the merger with Betriebsärzte Allgäu. The merger was carried out as part of an orderly succession plan, with three of the four partner doctors gradually stepping down from their senior management positions. They will, however, continue to work for the company as medical practitioners. The Arsipa Group is a Warburg Pincus portfolio company specialising in occupational medicine, occupational safety, occupational psychology and environmental protection. It has around 750 employees across more than 50 locations in Germany and Austria and provides services to over 20,000 companies. Betriebsärzte Allgäu is a partnership company founded in 2015 and based in Kempten. The team looks after more than 600 companies in the Allgäu region, focusing on occupational medicine while also providing complementary services in specialised areas such as traffic medicine, allergology and holiday/travel medicine. The practice primarily works with companies in the transport, logistics and industrial sectors, as well as with public sector organisations such as the German Armed Forces. Advisers of Arsipa at GSK Stockmann: Robert Korndörfer (lead, Partner, Corporate), Stephan Wachsmuth (Local Partner, Tax), Nicole Deparade (Local Partner, Employment Law), Dr Martin Hossenfelder (Counsel, IP/IT), Clara López Hernando (Senior Associate, Corporate), Katrin Zukovskaja (Associate, Employment Law), Dr Maximilian Schnebbe (Associate, Data Protection) ### Contact: GSK STOCKMANN Robert Korndörfer Anton-Wilhelm-Amo-Str. 42 10117 Berlin T +49 30 203907 - 93 F +49 30 203907-44 [email protected] Press contact: GSK STOCKMANN Christina Holl Karl-Scharnagl-Ring 8 80539 Munich T +49 89 288174-275 F +49 89 288 174-44 [email protected] GSK Stockmann is a leading independent European corporate law firm. Over 250 professionals advise German and international clients at our locations in Berlin, Frankfurt/M., Hamburg, Heidelberg, Munich, Luxembourg and London. GSK is the law firm of choice for Real Estate and Financial Services. We also have deep-rooted expertise in key sectors including Funds, Capital Markets, Public, Mobility, Energy and Healthcare. For international transactions and projects, we work together with selected reputable law firms abroad. Our advice combines an economic focus with entrepreneurial foresight. That is what is behind: Your perspective. More about us: www.gsk.de

On 28 May 2025, the European Commission adopted its EU Startup and Scaleup Strategy (the "Strategy") -  a coordinated EU-level framework designed to support the creation, growth and internationalisation of innovative startups and scaleups. The Strategy sets out 26 legislative, regulatory and financial measures intended to transform Europe into a global leader in tech-driven entrepreneurship. The Strategy in a nutshell Between 2008 and 2021, nearly 30 % of European unicorns relocated outside the EU, and only 8 % of global scaleups are Europe-based. In response, the Strategy focuses on five priority areas: fostering innovation-friendly regulation, improving access to finance, accelerating market uptake, attracting and retaining talent, and ensuring startups can access infrastructure and innovation ecosystems across Europe. Regulatory and structural reforms To address fragmentation within the Single Market, the Commission will propose an optional “28th regime”: a standalone EU-wide corporate legal framework tailored to startups and scaleups. This regime will operate in parallel with national company laws and offer simplified procedures across Member States. It is expected to reduce the cost of failure, streamline legal and tax obligations, and allow for incorporation within 48 hours (Q1 2026). A European Business Wallet will be introduced by Q4 2025. This tool will provide all EU economic operators with a digital identity and a secure way to share verified data and credentials, facilitating cross-border interaction with administrations. The upcoming European Innovation Act (Q1 2026) will create an EU framework for regulatory sandboxes – supervised environments where new products, services or models, can be tested without triggering all regulatory requirements. This may offer fund managers opportunities to support early-stage ventures in sensitive sectors (e.g. fintech, AI, biotech), under some conditions. The Act will also introduce a voluntary Innovation Stress Test. This tool will help Member States assess whether new or revised laws could unintentionally hinder innovation. Further reforms are planned in strategic sectors. The Commission will introduce or revise legislation to reduce regulatory complexity in biotechnology, life sciences, advanced materials and defence (starting 2025). It will also revise the Standardisation Regulation by Q2 2026 to make EU standards more accessible to startups and SMEs. Better finance for startups and scaleups The Strategy confirms that access to late-stage and scaleup capital remains a structural weakness across the EU. To address this, the Commission will support the launch of the Scaleup Europe Fund in 2026. This fund will be structured as a market-based, privately managed and co-financed vehicle. It will focus on direct equity investments in strategic sectors such as deep tech, AI, semiconductors, and biotechnology—areas typically requiring funding rounds above EUR 50 million. These are capital-intensive technologies where EU companies still rely heavily on non-European investors. The Scaleup Europe Fund will complement existing initiatives such as InvestEU and the European Tech Champions Initiative (ETCI), and will be anchored operationally and financially by the European Investment Bank Group (EIB). This initiative seeks to help EU-based scaleups stay and expand within the Single Market. In parallel, the Commission will develop a European Innovation Investment Pact, expected in 2026. Coordinated with the EIB Group and institutional investors (notably pension funds and insurers), the Pact will encourage long-term voluntary commitments to invest in EU venture capital funds, fund-of-funds structures and unlisted scaleups. Its objective is to channel private capital into high-growth sectors and deepen the EU private investment ecosystem. Finally, the Commission will revise the definition of “undertaking in difficulty” under EU State aid rules (Q2 2025), which currently excludes many growth-stage companies—particularly in capital-intensive industries—from public support schemes. The reform aims to enable these companies to benefit from co-investment mechanisms without being mischaracterised as distressed entities. The Commission will report on the implementation of the Strategy by end-2027 and calls on the European Parliament, the Council and Member States to fully support the 26 announced measures. Authors: Evelyn Maher, Partner and Mikail Ceylan, Senior Associate